AVITA Medical Inc (RCEL): Next-Year EPS Estimate 59.31%
As of 2026-10-16, AVITA Medical Inc (RCEL) has a next-year EPS growth estimate of 59.31%. Featured in 5 EPS revision reports, most recently on 2026-08-18.
On 2026-10-12, analyst consensus for RCEL's next-year EPS growth shifted from 59.35% to 59.31% — a negative change of 0.04 percentage points. The revised estimate has been sustained across 5 subsequent trading sessions. Current-year growth is projected at 45.66%.
What's Driving This
The primary driver is the August 19, 2026 analyst revision raising next-year EPS growth estimates to 59.31% from 53.06%. This upgrade plausibly reflects AVITA’s Q2 2026 results, where revenue rose 18% to $21 million, 2026 revenue guidance was raised, and management projected fourth-quarter cash flow breakeven. Positive follow-through in headlines, including record quarterly performance and a PermeaDerm study showing a 70% economic advantage, suggests momentum has continued beyond the initial revision.
Generated 2026-10-15 from news as of 2026-10-15
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Devices
- EPS growth next year
- 59.31%
- EPS growth this year
- 45.66%
- EPS next quarter (est)
- -$0.24
- Last price
- $13.04
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-16 | 59.31% | 45.66% | -$0.24 | $13.04 |
| 2026-10-15 | 59.31% | 45.66% | -$0.24 | $13.41 |
| 2026-10-14 | 59.31% | 45.66% | -$0.24 | $13.10 |
| 2026-10-13 | 59.31% | 45.66% | -$0.24 | $13.36 |
| 2026-10-12 | 59.31% | 45.66% | -$0.24 | $13.37 |
| 2026-10-11 | 59.35% | 45.64% | -$0.24 | $13.21 |
| 2026-10-10 | 59.35% | 45.64% | -$0.24 | $13.21 |
| 2026-10-09 | 59.35% | 45.64% | -$0.24 | $13.21 |
| 2026-10-08 | 59.35% | 45.64% | -$0.24 | $13.33 |
| 2026-10-07 | 59.35% | 45.64% | -$0.24 | $13.05 |
| 2026-10-06 | 59.35% | 45.64% | -$0.24 | $12.99 |
| 2026-10-05 | 59.35% | 45.64% | -$0.24 | $13.25 |
| 2026-10-04 | 59.35% | 45.64% | -$0.24 | $12.72 |
| 2026-10-03 | 59.35% | 45.64% | -$0.24 | $12.72 |
| 2026-10-02 | 59.35% | 45.64% | -$0.24 | $12.72 |
| 2026-10-01 | 59.35% | 45.64% | -$0.24 | $12.01 |
| 2026-09-30 | 59.35% | 45.64% | -$0.24 | $11.73 |
| 2026-09-29 | 59.35% | 45.64% | -$0.24 | $11.96 |
| 2026-09-28 | 59.35% | 45.64% | -$0.24 | $11.67 |
| 2026-09-27 | 59.35% | 45.64% | -$0.24 | $11.84 |
| 2026-09-25 | 59.35% | 45.64% | -$0.24 | $11.84 |
| 2026-09-24 | 59.35% | 45.64% | -$0.24 | $11.58 |
| 2026-09-23 | 59.35% | 45.64% | -$0.24 | $10.95 |
| 2026-09-22 | 59.35% | 45.64% | -$0.24 | $11.49 |
| 2026-09-21 | 59.35% | 45.64% | -$0.24 | $10.84 |
| 2026-09-20 | 59.35% | 45.64% | -$0.24 | $11.02 |
| 2026-09-18 | 59.35% | 45.64% | -$0.24 | $11.02 |
| 2026-09-17 | 59.35% | 45.64% | -$0.24 | $11.22 |
| 2026-09-16 | 59.35% | 45.64% | -$0.24 | $10.45 |
| 2026-09-15 | 59.35% | 45.64% | -$0.24 | $10.21 |
Reports Featuring RCEL
- 2026-08-18
Sandisk Surges 32.7% After EPS Revision; ARGX, RCEL Rally
- 2026-07-22
Forward Air (FWRD) surges 25.6% as EPS revision sparks rally
- 2026-07-21
FWRD Leads EPS Revision Surge with 26.7% Gain; AEHR, RCEL Follow
- 2026-07-20
RCEL leads with 27.9% gain on EPS revision; other healthcare stocks follow
- 2026-07-17
RCEL surges 26.9% on EPS revision; COTY, RH, BILL, CVI also gain
Recent News
- AVITA Medical Announces Positive PermeaDerm Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical OutcomesGlobeNewswire
- AVITA Medical to Host Investor Webinar BriefingGlobeNewswire
- AVITA Medical Announces Participation at Canaccord Genuity Growth ConferenceGlobeNewswire
- AVITA Medical Announces Participation at Canaccord Genuity Growth ConferenceGlobeNewswire
- AVITA Medical, Inc. Q2 2026 Earnings Call SummaryMoby
- Avita Medical Shares Surge After Record Second-Quarter PerformanceInvestorsHub
- AVITA Medical Inc (AVHHL) (Q2 2026) Earnings Call Highlights: Revenue Surges 18% to $21. ...GuruFocus.com
- AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow BreakevenGlobeNewswire
- AVITA Medical to Announce Second Quarter 2026 Financial ResultsGlobeNewswire
- AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn AssociationGlobeNewswire
Screen Performance
Aggregate stats across all 2082 tickers our top-EPS-revision screen has flagged over the past 198 days.
- Median return since detection
- -3.0%
- % of tickers in the green
- 43%
- Median return on winners
- +21.5%
- Large revisions captured
- 1886
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is AVITA Medical Inc's next-year EPS growth estimate?▾
As of 2026-10-16, AVITA Medical Inc (RCEL) has a next-year EPS growth estimate of 59.31%, based on analyst consensus.
When was the latest EPS estimate revision for RCEL?▾
The most recent revision occurred on 2026-10-12, when analysts adjusted the next-year EPS growth estimate from 59.35% to 59.31%.
What sector and industry does AVITA Medical Inc belong to?▾
AVITA Medical Inc operates in the Healthcare sector, specifically the Medical Devices industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RCEL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. AVITA Medical Inc (RCEL) appears here because it was detected by our daily top-EPS-revision-performer screen.